HARCIMY

Serial Number 99054000
730

Registration Progress

Application Filed
Feb 24, 2025
Under Examination
Jun 17, 2025
Approved for Publication
Apr 22, 2025
Published for Opposition
Apr 22, 2025
Registered

Basic Information

Serial Number
99054000
Deadline
June 17, 2026
Description
Statement of Use or 2nd Extension Due
Filing Date
February 24, 2025
Published for Opposition
April 22, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
730
Status Date
Jun 30, 2025
Application
Pending
Classes
005

Rights Holder

Cytokinetics, Incorporated

03
Address
350 Oyster Point Blvd
South San Francisco, CA 94080

Ownership History

Cytokinetics, Incorporated

Original Applicant
03
South San Francisco, CA

Cytokinetics, Incorporated

Owner at Publication
03
South San Francisco, CA

Legal Representation

Attorney
B. Brett Heavner
USPTO Deadlines 2 active 1 overdue
Deadline Type Event Code Deadline Date Days Until Priority Extension Available
OPPOSITION
Notice of Publication
NPUB May 22, 2025 46 days overdue Medium Until Jun 22, 2025
ITU SOU
Notice of Allowance Mailed - SOU Required
NOAM Dec 17, 2025 163 days High Until Jun 17, 2026
Next deadline: Notice of Allowance Mailed - SOU Required on December 17, 2025 (163 days)

Application History

13 events
Date Code Type Description
Jul 1, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 30, 2025 EX1G S SOU EXTENSION 1 GRANTED
Jun 30, 2025 EXT1 S SOU EXTENSION 1 FILED
Jun 30, 2025 EEXT I SOU TEAS EXTENSION RECEIVED
Jun 17, 2025 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 22, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 22, 2025 PUBO A PUBLISHED FOR OPPOSITION
Apr 16, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 26, 2025 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 26, 2025 DOCK D ASSIGNED TO EXAMINER
Feb 24, 2025 MAFR O APPLICATION FILING RECEIPT MAILED
Feb 24, 2025 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 24, 2025 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
pharmaceutical preparations for human use, namely, medications to treat cardiovascular conditions; pharmaceutical preparations to treat hypertrophic cardiomyopathies, heart failure, and heart failure with preserved ejection fraction

Classification

International Classes
005